Analyst Reco. Passage Bio, Inc.

Equities

PASG

US7027121000

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
1.32 ^USD	+8.20%		+14.78%	+30.69%

03-04	Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-04	Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Lowers Passage Bio's Price Target to $3 From $5, Maintains Outperform Rating	11-13	MT
Chardan Trims Price Target on Passage Bio to $9 From $11, Keeps Buy Rating	08/08/23	MT
Raymond James Trims Price Target on Passage Bio to $9 From $10, Keeps Outperform Rating	12/05/23	MT
Chardan Cuts Price Target on Passage Bio to $11 From $18, Keeps Buy Rating	15/12/22	MT
Citigroup Adjusts Price Target on Passage Bio to $5 From $7, Maintains Buy Rating	11/11/22	MT
Guggenheim Adjusts Price Target on Passage Bio to $11 From $13, Maintains Buy Rating	11/11/22	MT
Wedbush Trims Passage Bio's Price Target to $5 From $6, Keeps Outperform Rating	11/11/22	MT
Canaccord Genuity Starts Passage Bio at Buy With $8 Price Target	08/11/22	MT
Chardan Research Lowers Passage Bio's Price Target to $18 From $34, Maintains Buy Rating	05/08/22	MT
Wedbush Adjusts Passage Bio Price Target to $6 From $9, Maintains Outperform Rating	04/08/22	MT
Goldman Sachs Adjusts Price Target for Passage Bio to $2 From $4, Maintains Neutral Rating	17/05/22	MT
Raymond James Adjusts Passage Bio's Price Target to $10 from $24, Keeps Outperform Rating	17/05/22	MT
Wedbush Cuts Passage Bio's Price Target to $9 From $16, Citing PBKR03 Update, PBFT02 Timeline; Outperform Rating Kept	17/05/22	MT
Citigroup Adjusts Price Target on Passage Bio to $10 From $15, Reiterates Buy Rating	17/05/22	MT
Chardan Research Adjusts Passage Bio's Price Target to $34 From $43; Buy Rating Kept	11/03/22	MT
JPMorgan Downgrades Passage Bio to Neutral From Overweight	08/03/22	MT
Raymond James Adjusts Passage Bio's Price Target to $24 From $29, Keeps Outperform Rating	04/03/22	MT
Goldman Sachs Analyst Starts Passage Bio at Neutral, Down From Buy, Sets $6 Price Target	19/01/22	MT
BTIG Adjusts Passage Bio's Price Target to $16 From $25, Reiterates Buy Rating	18/01/22	MT
Chardan Adjusts Price Target on Passage Bio to $43 From $45, Maintains Buy Rating	05/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Passage Bio, Inc.

Equities

PASG

US7027121000

Analyst Reco.

Filters